Compare HNVR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | TLSA |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 155.3M |
| IPO Year | 2022 | 2017 |
| Metric | HNVR | TLSA |
|---|---|---|
| Price | $26.55 | $0.97 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $24.50 | N/A |
| AVG Volume (30 Days) | 50.4K | ★ 258.6K |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $106.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $0.87 |
| 52 Week High | $27.00 | $2.60 |
| Indicator | HNVR | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 70.55 | 39.53 |
| Support Level | $22.09 | N/A |
| Resistance Level | N/A | $1.45 |
| Average True Range (ATR) | 0.79 | 0.12 |
| MACD | 0.21 | -0.02 |
| Stochastic Oscillator | 87.36 | 15.32 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.